3-(2,3-Dihydro-1,4-benzodioxin-6-yl)-1-[4-ethyl-2-(β-D-glucopyranosyloxy)-6-hydroxyphenyl]-1-propanone
![3-(2,3-Dihydro-1,4-benzodioxin-6-yl)-1-[4-ethyl-2-(β-D-glucopyranosyloxy)-6-hydroxyphenyl]-1-propanone price.](/CAS/GIF/794564-44-6.gif)
|
- $220 - $1760
- Product name: 3-(2,3-Dihydro-1,4-benzodioxin-6-yl)-1-[4-ethyl-2-(β-D-glucopyranosyloxy)-6-hydroxyphenyl]-1-propanone
- CAS: 794564-44-6
- MF: C25H30O10
- MW: 490.4997
- EINECS:
- MDL Number:
- Synonyms:3-(2,3-Dihydro-1,4-benzodioxin-6-yl)-1-[4-ethyl-2-(β-D-glucopyranosyloxy)-6-hydroxyphenyl]-1-propanone;3-(2,3-Dihydro-1,4-benzodioxin-6-yl)-1-[4-ethyl-2-(β-D-glucopyranosyloxy)-6-hydroxyphenyl]-1-propanone;1-Propanone, 3-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-[4-ethyl-2-(β-D-glucopyranosyloxy)-6-hydroxyphenyl]-
2 prices
Selected condition：
Brand
- TRC
Package
- 10mg
- 100mg
- ManufacturerTRC
- Product numberD446480
- Product description3-(2,3-Dihydro-1,4-benzodioxin-6-yl)-1-[4-ethyl-2-(β-D-glucopyranosyloxy)-6-hydroxyphenyl]-1-propanone
- Packaging10mg
- Price$220
- Updated2021-12-16
- Buy
- ManufacturerTRC
- Product numberD446480
- Product description3-(2,3-Dihydro-1,4-benzodioxin-6-yl)-1-[4-ethyl-2-(β-D-glucopyranosyloxy)-6-hydroxyphenyl]-1-propanone
- Packaging100mg
- Price$1760
- Updated2021-12-16
- Buy
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|
| TRC | D446480 | 3-(2,3-Dihydro-1,4-benzodioxin-6-yl)-1-[4-ethyl-2-(β-D-glucopyranosyloxy)-6-hydroxyphenyl]-1-propanone | 10mg | $220 | 2021-12-16 | Buy |
| TRC | D446480 | 3-(2,3-Dihydro-1,4-benzodioxin-6-yl)-1-[4-ethyl-2-(β-D-glucopyranosyloxy)-6-hydroxyphenyl]-1-propanone | 100mg | $1760 | 2021-12-16 | Buy |
Properties
Boiling point :756.6±60.0 °C(Predicted)
Density :1.420±0.06 g/cm3(Predicted)
pka :7.46±0.40(Predicted)
Density :1.420±0.06 g/cm3(Predicted)
pka :7.46±0.40(Predicted)
Safety Information
| Symbol(GHS): | ||||||||
|---|---|---|---|---|---|---|---|---|
| Signal word: | ||||||||
| Hazard statements: |
|
|||||||
| Precautionary statements: |
|